The estimated Net Worth of Paul Mc Kenzie is at least $1.49 Milhão dollars as of 1 March 2019. Paul Kenzie owns over 568 units of Biogen Inc stock worth over $1,490,587 and over the last 8 years Paul sold BIIB stock worth over $0.
Paul has made over 6 trades of the Biogen Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Paul exercised 568 units of BIIB stock worth $113,083 on 1 March 2019.
The largest trade Paul's ever made was exercising 3,062 units of Biogen Inc stock on 12 February 2019 worth over $609,614. On average, Paul trades about 945 units every 91 days since 2017. As of 1 March 2019 Paul still owns at least 7,487 units of Biogen Inc stock.
You can see the complete history of Paul Kenzie stock trades at the bottom of the page.
Paul's mailing address filed with the SEC is BIOGEN INC., 225 BINNEY ST., CAMBRIDGE, MA, 02142.
Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner, eStelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Biogen Inc executives and other stock owners filed with the SEC include: